4592 Share Price Performance
JP¥3,850.00
2793.00 (264.24%)
Price JP¥3,850.00
Share PriceJP¥3,850.00
SanBio Company Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
4592 Community Narratives
There are no narratives available yet.
Recent 4592 News & Updates
SanBio Company Limited Key Details
Last Reported Earnings
Jul 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -49.56
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 104.8%
SanBio Company Limited Competitors
Snowflake Analysis
About 4592
- Founded
- 2001
- Employees
- 29
- CEO
- WebsiteView website
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Japanese Market Performance
- 7 Days: 2.1%
- 3 Months: 12.6%
- 1 Year: 17.2%
- Year to Date: 15.9%
Over the last 7 days, the market has risen 2.1%, driven by gains in every sector, especially the Industrials sector. As for the past 12 months, the market is up 17%. Earnings are forecast to grow by 8.0% annually. Market details ›